



TBOYCE@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3043

FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

JC1: 2d PCT/PTO 20 MAY 2002

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

5000

May 15, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 15, 2002	
Date	Thomas M. Boyce

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/069,744 entitled "CLINICAL USE OF THIAZOLIDINEDIONES ALONE OR IN CONJUNCTION WITH OTHER AGENTS TO BLOCK OXYTOCIN-MEDIATED ACTIONS SUCH AS UTERINE CONTRACTIONS IN PREMATURE LABOR OR LACTATION" by John A. Copland, III, et al.*
Client Reference: COPL-JA-98A

~~Our~~ Reference: UTSG:240US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (B1-B4, C1-C24).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201681/TMB.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.


Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508

TMB/cmb
Encl.: as noted

25165548.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
John A. Copland, III, *et al.*

Serial No.: 10/069,744

Filed: February 27, 2002

For: CLINICAL USE OF
THIAZOLIDINEDIONES ALONE OR IN
CONJUNCTION WITH OTHER AGENTS
TO BLOCK OXYTOCIN-MEDIATED
ACTIONS SUCH AS UTERINE
CONTRACTIONS IN PREMATURE
LABOR OR LACTATION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSG:240US/TMB

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

May 15, 2002
Date

Thomas M. Boyce
Thomas M. Boyce

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201681/TMB.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 15, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSG:240US/TMBSerial No.
10/069,744

List of Patents and Publications for Applicant's

Applicant
John A. Copland, III *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:
February 27, 2002Group:
Unknown

(Use several sheets if necessary)

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0783888	7/16/97	Europe			
	B2	EP 0861666	9/2/98	Europe			
	B3	WO 97/27191	7/31/97	PCT			
	B4	WO 98/39006	9/11/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Copland <i>et al.</i> , "Demonstration of functional oxytocin receptors in human breast Hs578T cells and their upregulation through a PKC-dependent pathway," <i>Endocrinology</i> , 140:2258-2267, 1999.
	C2	Dong <i>et al.</i> , "Involvement of calcitonin gene-related peptide in the modulation of human myometrial contractility during pregnancy," <i>J. Clin. Invest.</i> , 104:559-565, 1999.
	C3	Fuchs <i>et al.</i> , "Correlation between oxytocin receptor concentration and responsiveness to oxytocin in pregnant rat myometrium: effects of ovarian steroids," <i>Endocrinology</i> , 113:742-749, 1983.
	C4	Fuchs <i>et al.</i> , "Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor," <i>Science</i> , 215:1396-1398, 1982.
	C5	Grazzini <i>et al.</i> , "Inhibition of oxytocin receptor function by direct binding of progesterone," <i>Nature</i> , 392:509-512, 1998.
	C6	Hinko and Soloff, "Characterization of oxytocin receptors in rabbit amnion involved in the production of PGE ₂ " <i>Endocrinology</i> , 130:3547-3553, 1992.

25155754.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UTSG:240US/TMBSerial No.
10/069,744

List of Patents and Publications for Applicant's

Applicant
John A. Copland, III *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:
February 27, 2002Group:
Unknown

(Use several sheets if necessary)

U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Hinko and Soloff, "Up-regulation of oxytocin receptors in rabbit amnion by glucocorticoids. Potentiation by cyclic adenosine 3',5' monophosphate," <i>Endocrinology</i> , 133:1511-1519, 1993.
	C8	Hoare <i>et al.</i> , "The proximal portion of the cooH terminus of oxytocin receptor is required for coupling of Gg, but not Gi," <i>J. Biological Chem.</i> , 274:28682-28689, 1999.
	C9	Ip <i>et al.</i> , "Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion," <i>Cancer Res.</i> , 46:1735-1740, 1986.
	C10	Kimura <i>et al.</i> , "Expression of oxytocin receptor in human pregnant myometrium," <i>Endocrinology</i> , 137:780-785, 1996.
	C11	Larcher <i>et al.</i> , "Oxytocin receptor gene expression in the rat uterus during pregnancy and the estrous cycle and in response to gonadal steroid treatment," <i>Endocrinology</i> , 136:5350-5356, 1995.
	C12	Main, "Preterm Labor," The American College of Obstetricians and Gynecologists Technical Bulletin, No. 206, 1-10, June 1995.
	C13	McCormick, "The contribution of low birth weight to infant mortality and childhood morbidity," <i>N. Engl. J. Med.</i> , 312:82-90, 1985.
	C14	Moise <i>et al.</i> , "Indomethacin in the treatment of premature labor: effects on the fetal ductus arteriosus," <i>N. Engl. J. Med.</i> , 319:327-331, 1998.
	C15	Norton <i>et al.</i> , "Neonatal complications after the administration of indomethacin for preterm labor," <i>N. Engl. J. Med.</i> , 329:1602-1607, 1993.
	C16	Postina <i>et al.</i> , "Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V ₂ vasopressin receptor," <i>J. Biol. Chem.</i> , 271:31593-31601, 1996.
	C17	Reece and Homko, "Diabetes mellitus in pregnancy: what are the best treatment options?" <i>Drug Safety</i> , 18(3):209-220, 1998.
	C18	Soloff <i>et al.</i> , "Endocrine control of parturition," <i>Biology of the Uterus (2nd Edition)</i> , Wynn and Jollie (eds), Plenum Press, NY, pp. 559-607, 1989.
	C19	Soloff <i>et al.</i> , "Oxytocin receptors: triggers for parturition and lactation?" <i>Science</i> , 204:1313-1315, 1979.

25155754.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
UTSG:240US/TMBSerial No.
10/069,744

List of Patents and Publications for Applicant's

Applicant
John A. Copland, III *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
February 27, 2002Group:
UnknownU.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Strakova and Soloff, "Coupling of oxytocin receptor to G proteins in the rat myometrium during labor: G _i receptor interaction," <i>Am. J. Physiol.</i> , 272:E870-E876, 1997.
	C21	Strakova <i>et al.</i> , "ERK2 mediates oxytocin-stimulated PGE synthesis," <i>Am J. Physiol.</i> , 274:E634-E641, 1998.
	C22	Thornton <i>et al.</i> , "Progesterone metabolite and spontaneous myometrial contractions in vitro," <i>The Lancet</i> , 353:1327-1329, 1999.
	C23	Wilkins <i>et al.</i> , "Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents," <i>Am. J. Obstet. Gynecol.</i> , 159:685-689, 1988.
	C24	Williams <i>et al.</i> , "Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency," <i>Bioorganic & Medicinal Chemistry Letters</i> , 9:1311-1316, 1999.

25155754.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.